Delivery Order SPE2DB22D2206-SPE2DB25FKA13
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count units) on September 18, 2025, with completion scheduled for October 9, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $40,612.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count packaging) with an ultimate completion date of September 30, 2025. This competitive award, issued on September 9, 2025, carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $40,609.48 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 100 mg capsules (quantity 21s), with an ultimate completion date of October 2, 2025. This non-set-aside contract is to be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on August 13, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count packaging) on September 9, 2025, with a completion date of September 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside arrangement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,236.16 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg tablets (7-count units) on August 25, 2025, with completion scheduled for September 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) with a ceiling value of $8,123.96. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award is...
- The Defense Logistics Agency awarded a $8,123.96 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ibrance 75 mg tablets (quantity 7 units). This competitive, non-set-aside contract carries a firm fixed price and is scheduled for completion by September 5, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 100 mg capsules (21-count) with a ceiling value of $8,122.48. This firm fixed-price delivery order, which must be completed by September 16, 2025, is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The contract...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKA13Delivery Order
The Defense Logistics Agency awarded a $16,247.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Ibrance 75 mg capsules (quantity 21). This is a non-set-aside competitive award with an ultimate completion date of October 10, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal vendor for military and veteran healthcare systems. The company's DLA prime IDC enables comprehensive global pharmaceutical support across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies. This delivery order for Ibrance—a oncology medication—exemplifies the company's role in supplying specialized pharmaceutical products to support Defense Health Agency and other federal healthcare customers through the flexible and competitively-awarded contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 9/19/25 |